Bayer faces second investor reckoning over glyphosate litigation
FRANKFURT (Reuters) - Bayer (BAYGn.DE) on Tuesday faces its second annual investor reckoning over its handling of a wave of U.S. lawsuits claiming its glyphosate-based weedkillers cause cancer. FILE PHOTO: The logo of Bayer AG is pictured at the facade of the historic headquarters of the German pharmaceutical and chemical…
bubmagApril 28, 2020